S. Forman | Semantic Scholar

Publications
Influence

Claim Your Author Page

Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

M. Slovak, K. Kopecky, +9 authors F. Appelbaum

Medicine

Blood

2000

The associations of cytogenetics with complete remission (CR) rates, overall survival (OS), and outcomes after CR were studied in 609 previously untreated AML patients younger than 56 years old in a… Expand

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

M. Topp, N. Goekbuget, +22 authors H. Kantarjian

Medicine

The Lancet. Oncology

2015

BACKGROUND Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unfavourable prognosis. Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19,… Expand

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

C. Brown, D. Alizadeh, +19 authors B. Badie

Medicine

The New England journal of medicine

2016 (First Publication: 28 December 2016)

A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). Multiple… Expand

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.

W. Bensinger, P. Martin, +9 authors F. Appelbaum

Medicine

The New England journal of medicine

2001 (First Publication: 18 January 2001)

BACKGROUND In recipients of allogeneic hematopoietic-cell transplants, peripheral-blood cells mobilized with the use of filgrastim (recombinant granulocyte colony-stimulating factor) engraft more… Expand

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

B. Till, M. Jensen, +13 authors O. Press

Medicine

Blood

2008 (First Publication: 15 September 2008)

Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is a promising approach to cancer therapy that has not previously been explored for the treatment of lymphoma… Expand

Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.

F. Kaplan, M. Xu, +17 authors E. Shore

Biology, Medicine

Human mutation

2009 (First Publication: 1 March 2009)

Fibrodysplasia ossificans progressiva (FOP) is an autosomal dominant human disorder of bone formation that causes developmental skeletal defects and extensive debilitating bone formation within soft… Expand

Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.

E. McLaughlin-Taylor, H. Pande, +5 authors S. Riddell

Medicine, Biology

Journal of medical virology

1994 (First Publication: 1 May 1994)

Primary cytomegalovirus (CMV) infection and reactivation of persistent CMV are associated with significant morbidity and mortality in immunocompromised individuals. Although recovery from CMV disease… Expand

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

R. Bhatia, M. Holtz, +6 authors S. Forman

Medicine

Blood

2003 (First Publication: 15 June 2003)

The BCR/ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec, STI571; Novartis, Basel, Switzerland) has shown remarkable efficacy in the treatment of chronic myelogenous leukemia (CML), with a… Expand

Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.

Vinod Pullarkat, Marilyn L. Slovak, Kenneth J. Kopecky, Stephen J. Forman, Frederick R Appelbaum

Medicine

Blood

2008 (First Publication: 1 March 2008)

We examined the prognostic impact of cytogenetics on the outcome of 200 acute lymphoblastic leukemia (ALL) patients 15 to 65 years of age enrolled in Southwest Oncology Group (SWOG)-9400 study.… Expand

Solid cancers after bone marrow transplantation.

S. Bhatia, A. D. Louie, +12 authors S. Forman

Medicine

2001 (First Publication: 15 January 2001)

PURPOSE To evaluate the incidence and associated risk factors of solid cancers after bone marrow transplantation (BMT). PATIENTS AND METHODS We analyzed 2,129 patients who had undergone BMT for… Expand